Sanuwave Health initiated with an Outperform at Northland

Northland analyst Carl Byrnes initiated coverage of Sanuwave Health (SNWV) with an Outperform rating and $55 price target The company’s UltraMIST System, which addresses an unmet need in chronic wound care, is seeing strong adoption, says the analyst, who views Sanuwave as “a core holding for medtech investors.” The company’s “razor/razorblade model” drives recurring revenue and supports gross margins in the high-70% range, the analyst added.